AZD-5492

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameAZD-5492
Drug Alias NameAZD5492
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionAnti-CD20Anti-T-cell receptorAnti-Cluster of differentiation 8
TargetsB-lymphocyte antigen CD20T-cell receptorCluster of differentiation 8
Therapy Area/IndicationsLupus Erythematosus, SystemicMyositisArthritis, Rheumatoid +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbAstraZeneca global R & D (China) Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicMyositisArthritis, Rheumatoid +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A